Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · IEX Real-Time Price · USD
1.310
+0.050 (3.97%)
At close: May 2, 2024, 4:00 PM
1.301
-0.009 (-0.69%)
After-hours: May 2, 2024, 5:00 PM EDT

Aclaris Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018201720162015
Market Capitalization
93741,05089027878303760582543
Market Cap Growth
--92.92%17.97%220.59%254.99%-74.14%-60.21%30.72%7.12%-
Enterprise Value
-27-448337002354165567444458
PE Ratio
-0.84-0.84-12.08-9.80-5.44-0.48-2.28-11.10-12.10-23.48
PS Ratio
2.942.3835.30131.6742.8418.5149.18451.80--
PB Ratio
0.580.475.324.517.381.121.413.383.435.87
P/FCF Ratio
-0.93-0.93-15.41-16.98-7.10-0.80-2.96-13.60-16.70-26.01
P/OCF Ratio
-0.95-0.95-15.54-17.08-7.19-0.81-3.00-13.91-16.81-26.66
EV/Sales Ratio
-1.42-1.4228.01103.4636.230.9126.76336.62--
EV/EBITDA Ratio
0.500.50-9.68-7.78-4.71-0.02-1.26-8.10-9.27-22.38
EV/EBIT Ratio
0.500.50-9.59-7.70-4.59-0.02-1.24-8.05-9.24-22.28
EV/FCF Ratio
0.560.56-12.22-13.34-6.01-0.04-1.61-10.13-12.76-21.95
Debt / Equity Ratio
0.000.000.000.000.300.010.14---
Debt / EBITDA Ratio
0.000.00-0.01-0.01-0.230.00-0.23---
Debt / FCF Ratio
-0.01-0.01-0.01-0.01-0.29-0.01-0.29---
Quick Ratio
3.863.869.948.373.693.386.1615.2322.0554.58
Current Ratio
4.164.1610.568.943.873.746.5715.6922.2755.64
Asset Turnover
0.140.140.120.030.080.020.030.0100
Return on Equity (ROE)
-52.80%-52.80%-41.70%-47.80%-109.70%-136.00%-72.10%-34.30%-45.40%-64.50%
Return on Assets (ROA)
-40.20%-40.20%-33.90%-37.70%-62.90%-88.50%-60.70%-32.30%-43.20%-41.50%
Return on Capital (ROIC)
-78.84%-78.84%-42.94%-33.02%-99.21%-156.38%-34.58%-24.13%-28.65%-22.34%
Earnings Yield
-96.25%-118.96%-8.27%-10.21%-18.37%-206.27%-43.88%-9.01%-8.27%-4.26%
FCF Yield
-86.62%-107.07%-6.49%-5.89%-14.08%-125.36%-33.77%-7.35%-5.99%-3.84%
Buyback Yield / Dilution
-7.05%-7.05%-14.95%-33.36%-2.94%-25.57%-17.11%-31.22%-250.67%-255.04%
Total Shareholder Return
-7.05%-7.05%-14.95%-33.36%-2.94%-25.57%-17.11%-31.22%-250.67%-255.04%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).